Published in Acta Oncol on January 01, 1992
Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica (2010) 0.75
[Treatment of spinal cord compression caused by malignant disease]. Tidsskr Nor Laegeforen (1991) 2.04
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant (2001) 1.66
Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol (2001) 1.49
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol (1996) 1.45
Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant (1999) 1.44
Follow-up of breast cancer patients stage I-II: a baseline strategy. Eur J Cancer (1993) 1.39
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol (2002) 1.37
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol (1993) 1.35
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer (2000) 1.29
Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer (2004) 1.23
Extramedullary plasmacytomas and solitary plasma cell tumours of bone. Eur J Haematol (1990) 1.07
Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study. Acta Anaesthesiol Scand (2010) 1.06
Cells in peripheral leg lymph of normal men. Lymphology (1978) 1.04
Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart (1996) 1.03
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol (2002) 1.02
High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage (2000) 0.96
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival. Scand J Haematol (1985) 0.96
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer (1990) 0.96
High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol (1992) 0.95
Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? Ann Oncol (1996) 0.95
T-zone lymphoma with predominance of 'plasmacytoid T-cells' associated with myelomonocytic leukaemia--a distinct clinicopathological entity. J Pathol (1986) 0.94
Spontaneous (H)-thymidine uptake in histological subgroups of human B-cell lymphomas. Scand J Haematol (1981) 0.93
Immunological subsets in human B-cell lymphomas. Scand J Immunol (1981) 0.93
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer (1984) 0.92
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol (2001) 0.92
The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer (2007) 0.91
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant (2005) 0.91
DNA cell cycle distribution and glutathione (GSH) content according to circadian stage in bone marrow of cancer patients. Br J Cancer (1992) 0.91
A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand (1978) 0.91
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer (1989) 0.91
Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer (1997) 0.89
Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol (2001) 0.89
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol (1986) 0.87
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant (2001) 0.87
Cellular antitumor immune response in women with risk factors for breast cancer. Cancer Res (1979) 0.87
Effects of benzaldehyde on survival and cell-cycle kinetics of human cells cultivated in vitro. Eur J Cancer Clin Oncol (1983) 0.87
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Ann Hematol (2004) 0.87
Erdheim-Chester disease: case with chronic discharging sinus from bone. AJR Am J Roentgenol (1980) 0.86
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. Am J Pathol (1992) 0.86
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol (1999) 0.86
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer (1998) 0.85
Insulin-like growth factor-1 (IGF-1) has a costimulatory effect on proliferation of committed progenitors derived from human umbilical cord CD34+ cells. Stem Cells (1998) 0.85
A 10-year experience with splenectomy in patients with malignant non-Hodgkin's lymphoma at the Norwegian Radium Hospital. Cancer (1994) 0.84
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol (2004) 0.84
A population-based study of spinal metastatic disease in South-East Norway. Clin Oncol (R Coll Radiol) (2009) 0.83
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol (2004) 0.83
Cell-associated immunoglobulin in human non-Hodgkin lymphomas. A comparative study of surface immunoglobulin on cells in suspension and cytoplasmic immunoglobulin by immunohistochemistry. Acta Pathol Microbiol Scand A (1981) 0.83
No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide. J Hematother Stem Cell Res (2003) 0.82
Demecolcin and vinblastine sulphate as stathmokinetic agents for different tissues of the hairless mouse. Pathol Eur (1975) 0.82
Immunomagnetic removal of B-lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant (1988) 0.81
Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol (1995) 0.81
Tissue specificity of the epidermal chalones. Virchows Arch B Cell Pathol (1975) 0.81
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD. Cytotherapy (2001) 0.81
Effects of benzaldehyde on protein metabolism-of human cells cultivated in vitro. Eur J Cancer Clin Oncol (1983) 0.80
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant (2001) 0.80
Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol (1999) 0.80
[Diagnosis and treatment of solitary plasmacytoma]. Tidsskr Nor Laegeforen (1990) 0.80
Incorporation of fibrinogen into soluble fibrin complexes. Thromb Res (1974) 0.80
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy. Acta Oncol (1993) 0.80
Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies. Acta Oncol (1997) 0.80
Peripheral blood progenitor cell grafts contain high levels of platelet-secreted mediators. Transfusion (2001) 0.80
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. Int J Cancer (1987) 0.80
Humoral regulation of erythropoiesis and thrombopoiesis in appropriate and small for gestational age infants. Acta Paediatr Scand (1982) 0.79
Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers. Acta Oncol (1999) 0.79
[The radiotherapy satellite in Kristiansand--a model for Norwegian regional hospitals?]. Tidsskr Nor Laegeforen (2001) 0.79
[Vaccination against poliomyelitis]. Tidsskr Nor Laegeforen (1971) 0.79
Pain after palliative radiotherapy for spine metastases. Clin Oncol (R Coll Radiol) (2010) 0.79
Primary malignant lymphoma of the brain. A report of 24 cases from the Norwegian Radium Hospital. Acta Oncol (1992) 0.79
Whole-body distribution of radioactivity after intraperitoneal administration of 32P colloids. Br J Radiol (1984) 0.79
Delineation of subsets in human B-cell lymphomas by a set of monoclonal antibodies raised against B lymphoma cells. Scand J Immunol (1983) 0.78
No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol (2000) 0.78
Appearance of trabecular bone in the femoral neck (Singh index). Relation to vertebral bone mass post mortem. Acta Radiol Diagn (Stockh) (1979) 0.78
[Chemotherapy-induced hemolytic uremic syndrome. A complication to mitomycin treatment of breast carcinoma]. Tidsskr Nor Laegeforen (1995) 0.78
Karyotyping of a hematologic neoplasia developing shortly after treatment for cerebral extragonadal germ cell tumor. Cancer Genet Cytogenet (1991) 0.78
Immunoblastic lymphadenopathy with early onset in two boys: immunohistochemical study and indication of decreased proportion of circulating T-helper cells. Br J Haematol (1984) 0.78
Granulocytic sarcoma (chloroma) of the uterine cervix: report of two cases. Int J Gynecol Pathol (1983) 0.78
Isolation and characterization of heparin from human mastocytoma tissue. Thromb Haemost (1980) 0.77
Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas. Br J Cancer (1998) 0.77
Hexagonal crystals in the bone marrow in patients with myeloproliferative disease and preleukaemia. Scand J Haematol (1984) 0.77
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients. Eur J Haematol Suppl (2001) 0.77
Bone-marrow MR imaging before and after autologous marrow transplantation in lymphoma patients without known bone-marrow involvement. Acta Radiol (1997) 0.77
Serum ferritin and bone marrow haemosiderin in patients with malignancies and in healthy controls. Scand J Haematol (1982) 0.77
Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation. J Natl Cancer Inst (1988) 0.77
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant (1998) 0.77
Some aspects of the bonds interlinking soluble fibrin complexes in human plasma. Thromb Res (1975) 0.77